Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 22, 2018. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Discharging Managerial Responsibilities (PDMR) and a person closely associated with them (PCA).
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a transfer of 10,984 ordinary shares between accounts and a subsequent transfer to a spouse for nil consideration. The filing explicitly states there was no change in beneficial ownership.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine disclosure of a personal share transaction executed on February 22, 2018, involving Mrs. V A Whyte (Company Secretary) and Mr. I W Whyte (PCA).
Key Facts for Investor Verification
- Transaction Type: Transfer of 10,984 ordinary shares (ISIN: GB0009252882) for nil consideration.
- Parties Involved: Mrs. V A Whyte (Company Secretary) and Mr. I W Whyte (Spouse/PCA).
- Beneficial Ownership: The filing confirms no change in beneficial ownership occurred.
- Financial Impact: The transaction price was £0.00; no financial impact on the company's balance sheet is indicated.